Questcor Pharmaceuticals (QCOR) Misses Q3 Views
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) reports Q3 EPS of $0.02, 9 cents below the analyst estimate of $0.11. Revenue for the quarter was $13.9 million, which compares to the estimate of $22.89 million.
Sees full year gross margin 91-93%.
Sees full year gross margin 91-93%.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
